B2BROKER
8.9.2022 11:31:33 CEST | Business Wire | Press release
B2Broker is excited to introduce White Label cTrader, a new ready-made platform solution. Using the new product, brokers can access a wide range of features offered by the cTrader platform that can enhance their business growth and offer their customers comprehensive trading services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220908005100/en/
B2Broker Adds cTrader to Its White Label Platform Solutions (Graphic: Business Wire)
About cTrader White Label
White Label cTrader offers a high-end solution that is fully customizable to match your brand. The solution's wide range of features makes it appealing to both institutions and retail clients.
White Label cTrader has everything businesses need, with B2Broker taking care of integration, customer support, and more. Liquidity, licensing, and many other features are already in the package.
cBroker
cBroker is a back-office tool that facilitates the management of trade inquiries and customer accounts. It tracks all the data flowing through the system, providing complete control over your business.
cTrader Copy
With cTrader Copy, brokers can allow their clients to copy other traders' deals and provide their own strategies. cTrader Copy lets customers easily choose assets, investment amounts, and risk levels that suit their needs.
Open API
With the cTrader open API, building new tools or integrating existing ones is a breeze. Create an ideal user interface by customizing existing ones (like TradingView) or designing your own. Technical analysis indicators, graphics, and labels are customizable for a perfect trading experience.
Prime of Prime Liquidity Pool
Prime of Prime Liquidity Pool allows brokers to access some of the best prices for financial instruments. Thanks to Tier 1 liquidity, traders can access over a thousand instruments, including 110 FX symbols and 150 crypto CFDs, spanning many asset classes — Forex, metals, commodities, indices, cryptocurrencies, equities, and ETFs.
B2Broker and cTrader
B2Broker's White Label cTrader solution offers a complete brokerage business package for both startups and established companies.
"cTrader is a well-known platform with a proven track record of success, and it is used by all the market's top brokers. A quick search on the Appstore for cTrader will reveal all the major companies that use this platform.
We believe that in today's ultra-competitive markets, every broker must offer a wide variety of trading platforms to its clients. Otherwise, the broker would lose clients who wish to trade on the cTrader platform. In addition to the traditional trading capabilities provided by the MT platform, cTrader will almost certainly attract a new category of traders and investors.
When it comes to managing your crypto brokerage, and its algo capabilities, cTrader is one of the top solutions on the market.
Since 2021, we have been seeing a growing demand for cTrader among cryptocurrency brokers. Since many cTrader brokers use our liquidity offering, we decided to open a whole new world for brokers that want to grow more sophisticated and cater to traders' needs, rather than requiring them to use a single platform," B2Broker CEO Arthur Azizov.
White Label cTrader will have even more updates soon. With more benefits and features on the way, B2Broker is sure to continue impressing the fintech community with its innovative solutions!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005100/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AMP IT Announces New Funding Round to Scale Its Private EV Charging as a Service in Switzerland and Beyond12.5.2026 08:43:00 CEST | Press release
AMP IT, a Geneva-based energy and mobility company, today announced the successful completion of a new funding round to accelerate the deployment of its private EV charging and energy management platform across Switzerland and international markets. Founded in 2021, AMP IT develops, finances, installs, and operates smart EV charging infrastructure for residential buildings, commercial real estate, and corporate fleets. Through its charging-as-a-service model, the company combines infrastructure with its proprietary software, AMP IT Hub, delivering a fully integrated energy solution. The latest funding round, supported notably by the Swiss Technology Fund, brings AMP IT’s total funding to €7 million since inception. The capital will support operational scaling, further development of its software platform, and expansion into selected European markets. “Users are increasingly looking for solutions that are simple, efficient, and affordable which is exactly what we provide,” said Florian
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden12.5.2026 08:30:00 CEST | Press release
− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart Failure Therapies –− Pooled Analysis of Over 25,000 Patient-Years of Experience with TTR-Silencing RNAi Therapies Shows a Consistent Safety Profile, Including No Clinically Meaningful Ocular Effects of Vitamin A Lowering –− DemonsTTRate Study Designed to Generate Long-Term Real-World Evidence in More Than 2,000 Patients with ATTR-CM − Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), adding to the growing body of evidence supporting vutrisiran and reinforcing the durability of transthyretin (TTR) knockdown and its well-characterized safety profile. Vutrisiran is the first and only TTR silencer approved for ATTR-
Merz Therapeutics’ Activities at ISPRM 2026 Highlight the Importance of Patient-Centric Management in Upper and Lower Limb Spasticity: From Goal Setting to Optimal Dosing for Better Patient Outcomes12.5.2026 08:00:00 CEST | Press release
Merz Therapeutics to present 11 abstracts at ISPRM World Congress 2026, highlighting its commitment to improving outcomes for people living with movement disorders Updated analysis indicates that optimizing botulinum toxin dosing over multiple injection cycles may be an important factor in improving outcomes in people living with limb spasticity, with available clinical data suggesting support for flexible, individualized dosing with incobotulinumtoxinA (XEOMIN®) Updated meta-analyses examining secondary treatment failure and neutralizing antibodies suggest a potential for sustained long-term treatment response with incobotulinumtoxinA (XEOMIN®) Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced it will present 11 scientific abstracts at the International Society of Physical and Rehabilitation Medicine (ISPRM) 2026 World Congress. Taking place from May 17th to May 21st in Vancouver, Canada, the presentations will feature key data on optimal dosin
SES Delivers Robust Q1 2026 Results & Reiterates Full-Year Outlook12.5.2026 07:30:00 CEST | Press release
SES S.A. announces financial results for the three months ended 31 March 2026. Q1 2026 Performance (€ million) Q1 2026 as reported (1) Q1 2025 as reported (1) ∆ At constant FX (2) Q1 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.18 1.04 1.04 Revenue 847 509 +80.5% 909 +3.1% Adjusted EBITDA (4) 404 280 +57.0% 425 +5.0% 1) ‘Reported basis’ with Intelsat fully consolidated from 17 July 2025 2) ‘At constant FX’ refers to comparative figures restated at the current period FX rates to neutralise currency variations 3) ‘Like-for-like basis’ is as if Intelsat fully consolidated from 1 January 2024 4) Excluding operating expenses/income recognised in relation to U.S. C-band repurposing, other income non-recurring, fair value movement on contingent value rights and other significant special items (disclosed separately) Networks revenue up +106.0% yoy(1) supported by growth in Mobility (+207.8% yoy(1); including positive impact from a contract restructuring in Aviation) and Gov
GIGABYTE Unveils “Future Landing” at COMPUTEX 2026 as Implementation Becomes Critical to Scaling AI12.5.2026 03:00:00 CEST | Press release
GIGABYTE Technology, a global leader in high-performance computing, is taking its most comprehensive end-to-end portfolio for AI infrastructure to COMPUTEX 2026 under the theme "Future Landing." As AI transitions from training into large-scale inference and real-world operation, GIGABYTE addresses the industry's most pressing challenge: not whether AI can be built, but how quickly and reliably it can be deployed, operated, and sustained at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505299592/en/ GIGABYTE Unveils “Future Landing” at COMPUTEX 2026 as Implementation Becomes Critical to Scaling AI At COMPUTEX, GIGABYTE organizes its showcase around three states that define the lifecycle of production AI infrastructure. Ready: integrated systems that have been fully built, simulated, validated, and prepared for deployment. Deployable: modular clusters engineered for rapid implementation across diverse environments.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom